---
title: '2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and
  vomiting following moderately emetic risk antineoplastic agents'
date: '2023-12-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38114821/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231220170721&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSION: This antiemetic MASCC-ESMO guideline update includes new
  recommendations considering individual risk factors and the optimization of supportive
  anti-emetic ...'
disable_comments: true
---
CONCLUSION: This antiemetic MASCC-ESMO guideline update includes new recommendations considering individual risk factors and the optimization of supportive anti-emetic ...